GlassScriptPhysician profile
Steven Naymagon
NPI 1730349218
$86,501.63
in general payments reported to CMS, 2019-2025
39 companies · $47K in 2025
The $47K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,385 · 2020: $656 · 2021: $2,687 · 2022: $4,340 · 2023: $4,275 · 2024: $26K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Food and Beverage: $17K · Travel and Lodging: $10K · Education: $42.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,059.00 |
| Food and Beverage | $16,993.37 |
| Travel and Lodging | $10,338.12 |
| Education | $42.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $63,384.88 | 2019-2025 | Entyvio, Gattex |
| Abbvie INC. | $5,125.55 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,312.00 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $3,219.34 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $2,158.82 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $1,157.06 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $1,135.18 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $945.88 | 2019-2024 | Dificid |
| Janssen Scientific Affairs, LLC | $704.67 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $482.83 | 2023-2025 | Omvoh |
| Amgen INC. | $455.68 | 2021-2023 | Avsola, Amjevita |
| Ferring Pharmaceuticals INC. | $429.55 | 2019-2023 | Clenpiq |
| Ardelyx, INC. | $359.46 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $334.40 | 2022-2025 | Dupixent |
| Daiichi Sankyo INC. | $320.43 | 2019-2024 | Injectafer |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $295.16 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $279.35 | 2019-2024 | Linzess |
| Sandoz INC. | $277.35 | 2024-2025 | Hyrimoz |
| Aimmune Therapeutics, INC. | $273.31 | 2024-2025 | Vowst, Zenpep |
| Phathom Pharmaceuticals, INC. | $242.19 | 2024-2025 | Voquezna |
| Vivus LLC | $211.16 | 2023-2025 | Qsymia |
| Organon LLC | $190.86 | 2021-2025 | Hadlima |
| Exact Sciences Corporation | $170.52 | 2023-2025 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $153.90 | 2021-2024 | Talicia, Movantik, Aemcolo |
| Nestle Healthcare Nutrition INC. | $146.82 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.54 | 2023-2024 | Cyltezo |
| Celltrion USA INC. | $105.24 | 2024-2025 | Vegzelma, Zymfentra |
| Shire North American Group INC | $92.04 | 2019 | |
| Allergan, INC. | $73.33 | 2019-2020 | |
| Braintree Laboratories, INC. | $64.68 | 2021-2024 | Sutab, Suflave |
| Genzyme Corporation | $63.55 | 2022-2024 | |
| Boston Scientific Corporation | $53.67 | 2022-2023 | |
| Endo Pharmaceuticals INC. | $49.63 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $41.30 | 2023 | |
| Novo Nordisk INC | $23.81 | 2025 | Wegovy |
| Phadia US INC. | $18.85 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.74 | 2025 | |
| Intercept Pharmaceuticals, INC. | $16.11 | 2020 | |
| Apollo Endosurgery US INC | $9.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Naymagon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.